Delivery Order SPE2DB20D3103-SPE2DB21FQ2P1
- Not listed
- This federal contract award, valued at $5,345.05, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SHINGRIX VIAL KITS, a vaccine product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
- This federal contract award, valued at $1,854.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SHINGRIX VIAL KITS, a critical vaccine product, to support federal government healthcare programs. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, valued at $2,278.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SHINGRIX VIAL KITS, a vaccine product, with a performance period through May 28, 2025. The contract is a firm-fixed-price delivery order and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award, with a ceiling value of $7,658.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SHINGRIX vial kits, a vaccine product, with a completion date of September 13, 2024. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999...
- This federal contract award, valued at $9,703.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of SHINGRIX vial kits, a vaccine product, with an ultimate completion date of July 13, 2022. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $5,140.10. The contract is for the delivery of SHINGRIX VIAL KITS, a vaccine product, with a period of performance through December 17, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is a child contract under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,690.10, is for the delivery of SHINGRIX vial kits. This award is a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at up to $999,999,999.00 and runs through November 2026. The IDC serves as the primary...
- This federal contract award, valued at $4,288.33, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SHINGRIX vial kits, with a performance period through May 8, 2024. This award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026....
- This federal contract award, valued at $3,974.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of SHINGRIX VIAL KITS, a vaccine product, with a period of performance through October 23, 2024. This award is a part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $1,060.72 for the supply of SHINGRIX VIAL KITS, with a completion date of December 19, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB21FQ2P1Delivery Order
This federal contract award, with a ceiling value of $27,109.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SHINGRIX VIAL KITS, a vaccine product, to support military healthcare programs. The award is a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of $999,999,999 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.1k | 9/14/21 |